Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 569-573, 2009.
Artigo
em Chinês
| WPRIM
| ID: wpr-310044
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate long-term cost effectiveness of telbivudine and lamivudine for the treatment of CHB.</p><p><b>METHODS</b>Cost effectiveness was conducted from social health insurance perspective. A Markov model was established based on disease progression pattern and the data from the 2 years GLOBE clinical trial. The information of annual medical expenditure and quality-of-life assessment for different CHB-related diseases was obtained from literature. Incremental cost per life year or quality-adjusted life year gained was measured.</p><p><b>RESULTS</b>Compared with lamivudine, the incremental cost for 1 additional QALY gained with telbivudine in treating HBeAg-positive and -negative CHB were 5403 yuan and 28239 yuan in Beijing, as well 4916 yuan and 29618 yuan in Guangzhou, respectively. According to national economic burden of CHB-related diseases, the ICER with telbivudine vs lamivudine were 1282 yuan and 31565 yuan for HBeAg-positive and -negative CHB.</p><p><b>CONCLUSION</b>According to WHO recommendation for ICER threshold, telbivudine is cost effective in treating HBeAg-positive and -negative CHB, as compared to lamivudine.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pirimidinonas
/
Timidina
/
Sangue
/
DNA Viral
/
China
/
Epidemiologia
/
Cadeias de Markov
/
Custos de Medicamentos
/
Análise Custo-Benefício
/
Seguro de Assistência de Longo Prazo
Tipo de estudo:
Ensaio Clínico Controlado
/
Guia de Prática Clínica
/
Avaliação Econômica em Saúde
/
Estudo prognóstico
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
País/Região como assunto:
Ásia
Idioma:
Chinês
Revista:
Chinese Journal of Hepatology
Ano de publicação:
2009
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS